- Home
- ATYR vs TERN Comparison
ATYR vs TERN Comparison
Compare ATYR & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- TERN
- Stock Information
- Founded
- ATYR 2005
- TERN 2017
- Country
- ATYR United States
- TERN United States
- Employees
- ATYR N/A
- TERN N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- ATYR Health Care
- TERN Health Care
- Exchange
- ATYR Nasdaq
- TERN Nasdaq
- Market Cap
- ATYR 327.0M
- TERN 298.1M
- IPO Year
- ATYR 2015
- TERN 2021
- Fundamental
- Price
- ATYR $2.79
- TERN $2.35
- Analyst Decision
- ATYR Strong Buy
- TERN Buy
- Analyst Count
- ATYR 6
- TERN 5
- Target Price
- ATYR $18.60
- TERN $18.38
- AVG Volume (30 Days)
- ATYR 1.6M
- TERN 1.0M
- Earning Date
- ATYR 03-13-2025
- TERN 05-12-2025
- Dividend Yield
- ATYR N/A
- TERN N/A
- EPS Growth
- ATYR N/A
- TERN N/A
- EPS
- ATYR N/A
- TERN N/A
- Revenue
- ATYR $235,000.00
- TERN N/A
- Revenue This Year
- ATYR $1,387.23
- TERN N/A
- Revenue Next Year
- ATYR $873.22
- TERN N/A
- P/E Ratio
- ATYR N/A
- TERN N/A
- Revenue Growth
- ATYR N/A
- TERN N/A
- 52 Week Low
- ATYR $1.42
- TERN $2.32
- 52 Week High
- ATYR $4.66
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- ATYR 33.98
- TERN 24.66
- Support Level
- ATYR $3.20
- TERN $3.07
- Resistance Level
- ATYR $3.94
- TERN $3.72
- Average True Range (ATR)
- ATYR 0.22
- TERN 0.20
- MACD
- ATYR -0.09
- TERN -0.05
- Stochastic Oscillator
- ATYR 4.97
- TERN 2.22
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.